HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 01/02/2013 -- Atmel Corporation (NASDAQ:ATML) shares climbed 5.65% to $6.55. The company, on Dec. 19, announced that it has entered into a definitive agreement to acquire Ozmo, Inc. (Ozmo), a provider of ultra-low power Wi-Fi solutions that will expand Atmel’s wireless offerings and further enhance developers ability to design smart, connected devices, including devices targeted to ‘The Internet of Things’. Atmel expects the transaction to close by year. The financial terms of the acquisitions were not disclosed.
Will New Regulations Weigh over ATML Revenue Stream? Find Out Here
Zipcar Inc (NASDAQ:ZIP) manages almost 75 percent of the $400 million car-sharing segment in the United States. The overall market is estimated to hit $10 billion in the coming few years, Avis Chief Executive Ronald Nelson reported in a conference call with experts.
Zipcar’s business is almost five times bigger than Hertz’s and Enterprise’s car-renting businesses, Needham & Co analyst Kerry Rice stated.
Where Is Zipcar Inc Headed Exactly After Achieving This Milestone? Find Out Here
Linkedin Corporation (NYSE:LNKD) traded at $114.82 by increasing +1.71% with price volatility of 2.70% for a week and 2.42% for a month plus price volatility’s Average True Range for 14 days was 2.68.
Stocks after opening at $112.50 hit high price of $115.52 and on last session stock held volume of 1.10 million shares which was unexpectedly lower than its average volume of 1.54 million shares.
Is LNKD Showing Any Sign of Buy At The Current Market Price? Find Out Here
Synergy Pharmaceuticals (NASDAQ:SGYP) is up 17% but off day highs after the company reported that in its Phase IIb/III clinical study of plecanatide, its investigational oral drug for the treatment of chronic idiopathic constipation (CIC), plecanatide was well tolerated and met the primary and key secondary endpoints of a Phase IIb/III clinical study. The study was designed to determine whether plecanatide could increase the number of complete spontaneous bowel movements and impact other parameters in patients with CIC.
Is SGYP A Buy Or Sell At These Levels? Find Out Here
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)